1. Stem Cell Res. 2019 Dec;41:101626. doi: 10.1016/j.scr.2019.101626. Epub 2019
Oct  18.

Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound 
heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and 
p.R122* mutations in the AGXT gene.

Martinez-Turrillas R(1), Rodriguez-Diaz S(1), Rodriguez-Marquez P(1), 
Martin-Mallo A(1), Salido E(2), Beck BB(3), Prosper F(4), Rodriguez-Madoz JR(5).

Author information:
(1)Regenerative Medicine Program, CIMA Universidad de Navarra, Pamplona, Spain. 
Instituto de Investigación Sanitaria de Navarra, IdiSNA, Pamplona, Navarra, 
Spain.
(2)Hospital Universitario de Canarias, Universidad La Laguna, Tenerife, Spain. 
Centre for Biomedical Research on Rare Diseases (CIBERER).
(3)University of Cologne, Institute of Human Genetics and Center for Molecular 
Medicine Cologne (CMMC), University Hospital of Cologne, Cologne, Germany.
(4)Regenerative Medicine Program, CIMA Universidad de Navarra, Pamplona, Spain. 
Instituto de Investigación Sanitaria de Navarra, IdiSNA, Pamplona, Navarra, 
Spain; Area of Cell Therapy, Clinica Universidad de Navarra, University of 
Navarra, Pamplona, Spain. Instituto de Investigación Sanitaria de Navarra, 
IdiSNA, Pamplona, Navarra, Spain. Electronic address: fprosper@unav.es.
(5)Regenerative Medicine Program, CIMA Universidad de Navarra, Pamplona, Spain. 
Instituto de Investigación Sanitaria de Navarra, IdiSNA, Pamplona, Navarra, 
Spain. Electronic address: jrrodriguez@unav.es.

Primary Hyperoxaluria Type I (PH1) is a rare autosomal recessive metabolic 
disorder characterized by defects in enzymes involved in glyoxylate metabolism. 
PH1 is a life-threatening disease caused by the absence, deficiency or 
mistargeting of the hepatic alanine-glyoxylate aminotransferase (AGT) enzyme. A 
human induced pluripotent stem cell (iPSC) line was generated from dermal 
fibroblasts of a PH1 patient being compound heterozygous for the most common 
mutation c.508G>A (G170R), a mistargeting mutation, and c.364C>T (R122*), a 
previously reported nonsense mutation in AGTX. This iPSC line offers a useful 
resource to study the disease pathophysiology and a cell-based model for drug 
development.

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

DOI: 10.1016/j.scr.2019.101626
PMID: 31715429 [Indexed for MEDLINE]